跳至主要内容
临床试验/CTRI/2023/10/058922
CTRI/2023/10/058922尚未招募2 期

Efficacy of intravenous haloperidol as an adjuvant analgesic in the management of cancer pain in the Palliative care outpatient department – A prospective observational single arm study - NI

Cancer Institute WIA0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1)All patients who are diagnosed with abdominal cancer and, head and neck cancer, receiving morphine for pain management, in acute severe pain NRS = 7
  • 2)Age 18 – 65 years

排除标准

  • 1)People who are already on psychiatric medications or previous psychiatric disorder
  • 2)People in acute delirium or mentally incapacitated or has severe emotional or psychiatric disorder.
  • 3)People with history or current evidence of QT prolongation arrythmia or existing cardiovascular problems
  • 4)People with extrapyramidal symptoms or existing parkinsonism
  • 5)People who are hypotensive, hypothyroid, increased liver function tests
  • 6)People who are allergic to haloperidol
  • 7)People not consenting for the study or inability to give informed consent

研究者

相似试验